Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Licoricidin, is a potent anti-metastatic agent, which can markedly inhibit the metastatic and invasive capacity of malignant prostate cancer cells.
Description | Licoricidin, is a potent anti-metastatic agent, which can markedly inhibit the metastatic and invasive capacity of malignant prostate cancer cells. |
In vitro | This study examined whether HEGU and Licoricidin inhibit metastasis using the 4T1 mammary cancer model. Both HEGU and Licoricidin treatment reduced pulmonary metastasis and the expression of CD45, CD31, HIF-1α±, iNOS, COX-2, and VEGF-A in tumor tissues. Additionally, a decrease in protein expression of VEGF-R2, VEGF-C, VEGF-R3, and LYVE-1 was noted in tumor tissues of Licoricidin-treated mice. Furthermore, the blood concentrations of MMP-9, ICAM-1, VCAM-1, and VEGF-A were decreased in HEGU-treated mice. In vitro 4T1 cell culture results showed that both HEGU and Licoricidin inhibited cell migration, MMP-9 secretion, and VCAM expression[1] |
Molecular Weight | 424.53 |
Formula | C26H32O5 |
CAS No. | 30508-27-1 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Licoricidin 30508-27-1 Angiogenesis Immunology/Inflammation Proteases/Proteasome Tyrosine Kinase/Adaptors VEGFR MMP ROS Inhibitor inhibitor inhibit